A Proof-of-concept Study to Assess the Effect of (+)-SJ000557733 (SJ733) Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Trial Profile

A Proof-of-concept Study to Assess the Effect of (+)-SJ000557733 (SJ733) Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs SJ 733 (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 19 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top